Is the Human Papillomavirus (HPV) vaccine effective against new infections in a young adult with a history of sexual activity who has already received the vaccine at ages 19, 21, and 23?

HPV Vaccine Effectiveness Against New Infections in Previously Vaccinated Young Adults

Yes, the HPV vaccine remains highly effective at preventing new infections with HPV types you have not yet been exposed to, even after completing vaccination at ages 19,21, and 23 with a history of sexual activity. 1

Key Principle: The Vaccine is Prophylactic, Not Therapeutic

The HPV vaccine works by preventing new HPV infections—it does not treat existing infections or prevent progression of current infections to disease. 1 This is the most critical concept to understand about ongoing protection.

• HPV vaccine efficacy is high (>99%) among persons who have not been exposed to vaccine-type HPV before vaccination. 2, 3
• Most sexually active adults have been exposed to some HPV types, but not necessarily all of the HPV types targeted by vaccination. 1
• No clinical antibody test can determine whether you are already immune or still susceptible to any given HPV type. 1

Protection Against Future Exposures

The vaccine continues to protect you against any vaccine-type HPV strains you have not yet encountered, regardless of your sexual history. 4

• Even sexually active individuals aged 16-26 years demonstrated protection against persistent infection, precancerous lesions, and genital warts caused by HPV types within the vaccine. 5, 4
• Most sexually active females are expected to receive substantial benefit from immunization because they are unlikely to have been infected with all HPV types included in the vaccine. 4
• The 9-valent vaccine protects against HPV types 6,11,16,18,31,33,45,52, and 58—it is statistically unlikely you have been exposed to all nine types. 6, 3

Age-Related Effectiveness Considerations

Vaccine effectiveness is highest when given before sexual debut, but remains effective at preventing new infections at any age. 6, 7

• Vaccine effectiveness estimates for adolescents ages 15-18 years ranged from 12% to 90%, with the variation largely dependent on prior HPV exposure patterns. 7
• At any age, having a new sex partner is a risk factor for acquiring a new HPV infection, meaning ongoing protection remains relevant. 1
• The vaccine does not lose its ability to prevent infection with HPV types you haven't encountered—the reduced "effectiveness" in older populations reflects higher rates of prior exposure, not reduced vaccine potency. 6, 8

Critical Caveat About Prior Infections

There was no clear evidence of protection from disease caused by HPV types for which study participants were PCR-positive and/or seropositive at the time of vaccination. 8

• If you were already infected with a specific HPV type (e.g., HPV 16) at the time of vaccination, the vaccine will not clear that infection or prevent its progression. 1
• However, the vaccine will still protect you against the other 8 HPV types in the 9-valent vaccine that you have not been exposed to. 3

Ongoing Screening Remains Essential

Cervical cancer screening must continue according to current guidelines regardless of vaccination status, as the vaccine does not protect against all oncogenic HPV types. 4

• The 9-valent vaccine covers HPV types responsible for approximately 70-90% of cervical cancers, but not all carcinogenic types. 6, 3
• Cervical cancer screening guidelines and recommendations should be followed. 1

Duration of Protection

Current evidence shows sustained protection for at least 10+ years after vaccination, with no evidence of waning immunity requiring boosters. 6

• Longer-term surveillance continues to monitor for breakthrough lesions to determine if boosters are needed. 8
• Antibody responses remain robust years after vaccination, particularly when given at younger ages. 5